| TAH Drug Code | OSALA |
|---|---|
| Indications | Treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head & neck. Treatment of symptoms of dry mouth in patients with Sjogren's syndrome. |
| Dosing | Head & neck cancer - Radiation-induced xerostomia: Initially 5 mg TID. Usual dosage range: 15-30 mg daily (do not exceed 10 mg/dose). Sjogren's syndrome - Xerostomia: 5 mg QID. |
| Hepatic Impairment | Dose adjustment required |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Uncontrolled asthma, acute iritis & angle closure glaucoma. |
| Adverse Effects | Sweating, nausea, diarrhea, chills, flushing, urinary frequency, dizziness, asthenia, headache, dyspepsia, lacrimation, edema, abdominal pain, amblyopia, vomiting, pharyngitis, hypertension. |
| Pregnancy | No (Limited) Human Data – Animal Data Suggest Moderate Risk |
| Lactation | No (Limited) Human Data - Probably Compatible |
| More Info | UpToDate |